Frameless stereotactic radiosurgery for the treatment of primary intracranial tumours in dogs1. (6th September 2013)

• Record Type: Journal Article
• Authors: Mariani, C. L.; Schubert, T. A.; House, R. A.; Wong, M. A.; Hopkins, A. L.; Barnes Heller, H. L.; Milner, R. J.; Lester, N. V.; Lurie, D. M.; Rajon, D. A.; Friedman, W. A.; Bova, F. J.
• Is Part Of: Veterinary and comparative oncology. Volume 13:Number 4(2015:Dec.)
• Page Start: 409
• Page End: 423
• Publication Date: 2013-09-06
• Subjects: Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12056
• Languages: English
• ISSNs: 1476-5810

Abstract

<abstract abstract-type="main" id="vco12056-abs-0001"> <title>Abstract</title> <p id="vco12056-para-0001">Stereotactic radiosurgery (SRS) is a procedure that delivers a single large radiation dose to a well‐defined target. Here, we describe a frameless SRS technique suitable for intracranial targets in canines. Medical records of dogs diagnosed with a primary intracranial tumour by imaging or histopathology that underwent SRS were retrospectively reviewed. Frameless SRS was used successfully to treat tumours in 51 dogs with a variety of head sizes and shapes. Tumours diagnosed included 38 meningiomas, 4 pituitary tumours, 4 trigeminal nerve tumours, 3 gliomas, 1 histiocytic sarcoma and 1 choroid plexus tumour. Median survival time was 399 days for all tumours and for dogs with meningiomas; cause‐specific survival was 493 days for both cohorts. Acute grade III central nervous system toxicity (altered mentation) occurred in two dogs. Frameless SRS resulted in survival times comparable to conventional radiation therapy, but with fewer acute adverse effects and only a single anaesthetic episode required for therapy.</p> </abstract>